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The intraperitoneal administration of chemotherapeutic and biological agents as therapy of
ovarian carcinoma is based on both theoretical considerations and experimental evaluations
which suggest that tumor present in the cavity can be exposed to higher concentrations ofcertain
antineoplastic drugs than can be accomplished if the agents are administered systemically.
Recent clinical data have confirmed both the safety and pharmacokinetic advantage associated
with this approach. Surgically defined responses have been observed in patients with small-
volume residual refractory ovarian carcinoma treated with several single-agent and combination
intraperitoneal therapeutic programs. While significant activity has been noted in this clinical
setting, a clearly defined role for intraperitoneal treatment in the standard management of
ovarian carcinoma remains to be determined.
The intraperitoneal administration ofchemotherapeutic agents in the management
ofovarian carcinoma began in the 1950s with the introduction ofnitrogen mustard as
an antineoplastic drug [1,2]. Unfortunately, theintraperitoneal instillation ofthe early
alkylating agents, while occassionally resulting in impressive control of malignant
ascites formation, was also associated with considerable local toxicity. In addition,
objective anti-tumor responses were rarely observed. Thus, intraperitoneal therapy
became relegated to those situations where it was desired to provide only temporary
control of ascites formation to improve the quality of the patient's life when all other
therapeutic options were eliminated.
It was not until the late 1970s that interest was renewed in the concept ofemploying
intraperitoneal chemotherapy as a therapeutic approach to treat tumors confined to
the peritoneal cavity. This renewed interest was based on the publication of a
mathematical model, developed by investigators at the National Cancer Institute,
which suggested that exposure of tumors in the peritoneal cavity to concentrations of
cytotoxic agents instilled directly into the cavity would far exceed the level ofexposure
achieved following systemic drug administration [3,4].
A number of important principles supporting and limiting the clinical use of
intraperitoneal chemotherapy have been defined in pre-clinical studies conducted at
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several centers[5]. These basic principles are presented below in outline form:
1. Agents most suitable for intraperitoneal administration are those which slowly
exit the peritoneal cavity following intraperitoneal administration and which
are rapidly cleared from the systemic circulation upon entry into that
compartment. These properties maximize cavity exposure to the agent while
minimizing systemic exposure and the potential for systemic toxicity [3,4].
2. Agents which are rapidly and extensively metabolized into non-toxic metabo-
lites during their first passage through the liver are particularly attractive for
intraperitoneal administration, as uptakeofdrugs from the peritoneal cavity is
largely via the portal circulation [6,7].
3. Penetration ofchemotherapeutic agents directly into tumor tissue is limited to
a depth of several cell layers to several millimeters [5,8-12]. This fact would
strongly suggest that any benefit to begained from intraperitoneal chemother-
apy would be limited to those situations where only very small tumor volume
remains in the cavity, either following surgical debulking alone or debulking
surgery plus systemic chemotherapy.
4. As any benefit to be gained from intraperitoneal chemotherapy (over that
accomplished with systemic drug administration) would rely onfree surface
diffusion ofthe agent in direct contact with tumor tissue, it is critical that the
drug reach all regions of the cavity following instillation. Large treatment
volumes (.2 liters) appear to optimize drug distribution [13-15]. Unfortu-
nately, for several reasons, including both surgery- and chemotherapy-induced
adhesion formation, it cannot be assumed that all patients will achieve
adequate distribution ofdrug-containing fluid following intraperitoneal treat-
ment.
5. One major theoretical concern associated with the intraperitoneal instillation
of antineoplastic agents is that drug delivery to tumor by capillaryflow (the
mechanism by which the drug reaches the tumor following systemic adminis-
tration) will be diminished. Thus, it is argued, even if local exposure is
increased, overall exposure of the tumor to the antineoplastic agent may be
reduced. Ifcytotoxic drugs which are not locally toxic to the peritoneal lining
are selected for intraperitoneal therapy, it is possible to escalate the amount of
drug delivered to the point where dose-limiting toxicity will be the systemic
side effects ofthe agent [5]. In such a situation, exposure ofthe plasma (and,
ultimately, the tumor by capillary flow) to the antineoplastic agent following
intraperitoneal administration will equal thataccomplished following systemic
drug delivery. Thus, an important goal in designing intraperitoneal treatment
programs should be to select agents which do not produce such severe local
toxicity that systemic exposure is compromised. If, however, drugs are
employed which are limited by local toxic effects, it must be understood that
systemic exposure to the agent(s) will be diminished compared to that
achieved with intravenous delivery.
6. Finally, a number ofinvestigators have explored various options for delivering
intraperitoneal therapy in a safe and convenient manner [5,16]. While
percutaneous catheter placement with each treatment course is certainly an
option [17], there is genuine concern that bowel perforation may result,
particularly in individuals without ascites and those who have undergone one
or more previous laparotomies with subsequent adhesion formation [18].
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TABLE 1
Chemotherapeutic Agents
Examined for Their Safety,
Pharmacokinetic Advantage, and
Possible Efficacy in Ovarian
Carcinoma
Cisplatin
Carboplatin
5-fluorouracil
Doxorubicin
Mitoxantrone
Melphalan
Mitomycin-C
Methotrexate
Cytarabine
Etoposide
Surgically implanted catheters (the Tenckhoff type) reduce the risk of this
complication of therapy [19-21]. When these implanted catheters are
attached to subcutaneous delivery devices, patient acceptance of the catheter
improves and the incidence of catheter-related infections, the major problem
associated with these devices, appears to decrease [18,21].
SINGLE-AGENT TRIALS OF INTRAPERITONEAL
CHEMOTHERAPY IN OVARIAN CARCINOMA
A number of chemotherapeutic agents have been examined for their safety,
pharmacokinetic advantage, and efficacy when delivered by the intraperitoneal route
in the treatment ofovarian carcinoma (Table 1) [5]. Table 2 presents the pharmacoki-
netic advantage associated with selected agents when administered by the intraperito-
neal route.
In the following section, the results of phase I and phase II trials examining a
potential role for single-agent intraperitoneal chemotherapy in the management of
ovarian carcinoma will be briefly summarized.
Cisplatin
Due to its central place in the management of ovarian carcinoma, it is logical that
cisplatin would be one ofthe first drugs to be examined for intraperitoneal administra-
tion [22]. A number of phase I and phase II trials employing this agent in the
management of refractory ovarian carcinoma have been reported [12,15,23-27]. The
results of these trials are outlined in Table 3. A reasonable dose of cisplatin
administered as a single agent by the intraperitoneal route is 100 mg/M2.
It is important to note that there is a strong experimental basis to support the
intraperitoneal use ofcisplatin in refractory ovarian carcinoma. Several investigators
have noted that, under experimental conditions, it is difficult to make human ovarian
carcinoma cells more than two to five times resistant to cisplatin either in vitro or in
vivo [28]. In theory this finding means that if it were possible to expose a tumor to
somewhat higher concentrations ofcisplatin (i.e., eight to ten times higher doses than
the standard used in initial treatment regimens) it is conceivable that clinical
resistance to cisplatin might be overcome.
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TABLE 2
Pharmacokinetic Advantage Associated with the Intraperitoneal
Administration of Selected Antineoplastic Drugs
Mean Peak Peritoneal Cavity/Plasma
Agent Concentration Ratio
Cisplatin 20
Carboplatin 18
5-FU 298
Doxorubicin 474
Mitoxantrone 620
Melphalan 93
Mitomycin-C 71
Unfortunately, it is not possible to significantly increase the dose of systemically
delivered cisplatin to patients beyond that which is the standard used (100-120
mg/M2) due to the development ofsevere side effects-principally neurotoxicity [22].
As noted in Table 3, however, following intraperitoneal administration, theexposureof
the peritoneal cavity to the agent is approximately 10 to 20 times greater than that of
the systemic circulation. Thus, at least in those situations where residual ovarian
carcinoma is present in only very small volumes following cisplatin-based systemic
therapy (microscopic disease only or tumor nodules c0.5 cm), it might be possible to
kill a major portion of the remaining tumor by using the same agent delivered by the
intraperitoneal route. An interesting approach has been examined at the University of
California, San Diego, utilizing intraperitoneal cisplatin and a systemically delivered
neutralizing agent for the cytotoxic drug (sodium thiosulfate) [15]. This group has
demonstrated that single-agent cisplatin can be administered intraperitoneally up to
doses of270 mg/m2 with acceptable systemic toxicity.
Carboplatin
Compared to cisplatin, there has been far less experience using carboplatin
administered by the intraperitoneal route. In several phase I trials, this agent has been
shown to produce limited or no local toxicity and to possess a pharmacokinetic
advantage which approximates that found with cisplatin [29-31]. Not surprisingly,
dose-limiting toxicity has been bone marrow suppression, principally thrombocytope-
TABLE 3
Summary of Phase I-II Trials Employing Intraperitoneal Cisplatin in Refractory
Ovarian Carcinoma
Pharmacokinetic advantage: 10- to 20-fold increased exposure ofthe peritoneal cavity
following intraperitoneal delivery as compared to the systemic circulation
Dose-limiting toxicity: Systemic effects ofthe agent
Local toxicity: Minimal or no abdominal pain following intraperitoneal instillation
Surgical findings: Mild to moderate "filmy" adhesions noted
Long-term complications: Todate, none appreciated
Efficacy: 30-50 percent ofpatients with "small-volume" refractory ovarian carcinoma
will experience a surgically documented response (CR or PR)
CR, complete response
PR, partial response
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nia. Surgically defined responses, including complete responses in patients with
small-volume residual ovarian carcinoma, have been observed. The reported trials have
demonstrated that carboplatin can be safely administered by the intraperitoneal route
as a single agent at a dose of approximately 300 mg/M2. In patients with mild to
moderate compromise of renal function (creatinine clearance 30-60 ml/minute) the
dose ofcarboplatin should be reduced to 200-250 mg/m2.
5-Fluorouracil (5-FU)
5-FU was one of the first drugs to be examined for a role following intraperitoneal
delivery because it was known that the agent is rapidly metabolized during its first
passage through the liver [32]. As 5-FU has also been shown to possess activity in
ovarian carcinoma [33], investigators at the National Cancer Institute conducted a
phase II trial of this agent, delivered by the intraperitoneal route, in patients with
refractory ovarian carcinoma [34]. This treatment program called for 5-FU to be
administered at a concentration of 4 mM in eight consecutive two-liter dialysis
exchanges (four-hour duration/exchange). The procedure was repeated every two
weeks for six cycles unless there was evidence of disease progression. Unfortunately,
only one of 14 patients (7 percent) responded to the treatment program; this individual
experienced a surgically defined complete response, and a majority of patients
participating in this program had previously received systemically delivered 5-FU. As
most initial intravenous treatment regimens in ovarian carcinoma do not currently
include 5-FU, it is possible greater activity would now be observed for this drug
delivered by the intraperitoneal route in the refractory disease setting [22].
Doxorubicin
Doxorubicin is an active drug in the treatment ofovarian carcinoma and pre-clinical
data has suggested that it might be very effective in this disease when delivered by the
intraperitoneal route [33,35-36]. Unfortunately, while responses to intraperitoneal
doxorubicin in refractory ovarian carcinoma have been observed, local toxicity
(abdominal pain, adhesion formation, ascites production) has been severe [37-39].
Abdominal pain was observed in most patients with intraperitoneal doxorubicin doses
of .20 mg. In view ofthis toxicity pattern, investigators have not continued to pursue
the use ofthis agent for intraperitoneal administration in ovarian carcinoma.
Mitoxantrone
Mitoxantrone is a chemotherapeutic agent with an efficacy and toxicity pattern
which is quite similar to that of doxorubicin [40]. The agent has demonstrated
significant activity in ovarian carcinoma when delivered intravenously [41]. Analysis
of the activity of a large number of drugs against refractory ovarian carcinoma in a
short-term clonogenic assay has suggested that mitoxantrone is perhaps the most
active agent against ovarian carcinoma at concentrations which can be achieved in the
peritoneal cavity [42].
As thedrug is known to produce far less irritation totissues than does doxorubicin, it
was quite natural that investigators at a number of institutions initiated phase I trials
of intraperitoneal mitoxantrone in refractory ovarian carcinoma [43-46]. These
studies have confirmed the pharmacokinetic advantage ofthe intraperitoneal adminis-
tration of mitoxantrone and the relative safety of the agent when delivered by the
intraperitoneal route; however, dose-limiting toxicity of this drug continues to be
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abdominal pain and adhesion formation (with mitoxantrone doses of >20 mg/M2).
Objective responses, including surgically defined complete remissions, have been
noted. Of interest is the fact that activity for intraperitoneal mitoxantrone has been
observed in patients who have previously received systemically delivered doxorubicin
[47]. Phase II trials ofsingle-agent intraperitoneal mitoxantrone in refractory ovarian
carcinoma are currently in progress [47].
Melphalan
Several groups have examined the intraperitoneal administration of melphalan in
ovarian carcinoma [48,49]. In addition to confirming a modest pharmacokinetic
advantage associated with this route of drug delivery, the drug has been shown to
produce limited local toxicity. Little activity has been observed in refractory ovarian
carcinoma. This result is not surprising in view ofthe known limited clinical utility for
alkylating agents in the treatment ofrefractory disease [22,50,51].
The use ofthis agent as part ofinitial chemotherapy for ovarian carcinoma would be
ofgreater interest. As the doseofintraperitoneally administered drug can be escalated
to the point where systemic toxicity (bone marrow suppression) is dose-limiting, the
concentration ofdrug reaching the tumor by capillary flow (as previously discussed in
this review) should not be compromised when this route ofdrug delivery is employed
[49].
Mitomycin-C
Mitomycin-C has been included in a number of second-line systemic regimens for
ovarian carcinoma [52,53]. Several investigators have examined its use for intraperito-
neal administration in ovarian carcinoma and other intra-abdominal malignancies
[54,55]. Dose-limiting toxicity is the development of abdominal pain and severe
adhesion formation with mitomycin doses exceeding 10 mg/m2/course [56]. A recent
report from the University of Arizona Cancer Center has demonstrated clinical
responses (falls in CA-125 antigen, conversion of positive peritoneal cytologies to
negative) in a number of patients with refractory ovarian carcinoma treated with
intraperitoneal mitomycin (10 mg/M2every fourweeks) [54]. At the timeofthe report
on their initial experience using this treatment regimen, eightofthe 14 treated patients
remained without evidence ofdisease with a median follow-up often months.
Additional Single-Agent Intraperitoneal Trials in Ovarian Carcinoma
A number ofother agents have been examined for a potential role when delivered by
the intraperitoneal route in ovarian carcinoma. A pharmacokinetic advantage and
limited evidence of clinical activity has been observed for methotrexate [57,58],
cytarabine [59], and etoposide [60,61]. In theory, drugs with limited activity in
ovarian carcinoma may be ofgreater interest when used in a combination intraperito-
neal regimen if there is experimental evidence of concentration-dependent synergy
between the drugs included in the program [5].
COMBINATION INTRAPERITONEAL THERAPY IN THE
MANAGEMENT OF OVARIAN CARCINOMA
Based on previously reported data suggesting the superiority of combination
chemotherapy oversingleagents in the managementofovariancarcinoma, it was quite
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natural that combination intraperitoneal regimens would be examined in this disease
[62]. A number ofphase I combination intraperitoneal programs in ovarian carcinoma
have been reported. Most multi-agent programs have employed cisplatin as the
principal cytotoxic agent. Drugs used in addition to cisplatin have included etoposide
[60], melphalan [62], 5-FU [63,64], cytarabine [65], cytarabine/doxorubicin [66],
and cytarabine/bleomycin [67,68]. Cytotoxic agents have been selected based both on
clinical experience employing the drugs systemically in ovarian carcinoma and on
theoretical considerations (i.e., experimental evidence of concentration-dependent
synergy between the agents) [5].
It is important to note that the majority ofcombination and single-agent intraperito-
neal trials in ovarian carcinoma have not required that patients undergo a laparotomy
to assess response [69]. In the absence of such information it is difficult to know if
patients with small-volume residual disease (that subpopulation with the greatest
chance of benefiting from intraperitoneal treatment) have actually responded to
therapy. A "clinical complete repsonse" has little if any meaning in this patient
population, and published studies utilizing this end-point must be interpreted with
caution. While overall survival is an important end-point, it is difficult to compare
patient groups treated on different phase I or phaseII trials. In addition, it is known
that patients with small-volume residual ovarian carcinoma may survive for a number
of years following the documentation of persistent disease after intravenous chemo-
therapy [70-72]. Therefore, a two- or three-year disease-free survival following
intraperitoneal therapy may only reflect the natural history of disease rather than a
major effect of treatment.
A recent report from the Memorial Sloan-Kettering Cancer Center of a phase II
trial of combination intraperitoneal cisplatin and etoposide in refractory ovarian
carcinoma has helped to define further a patient population most likely to benefit from
this therapeutic approach [73]. The 20 evaluable patients with no tumor nodules >0.5
cm in diameter had a 55 percent surgically documented response rate (CR or PR)
compared to a 17 percent response rate (all PRs) in the 24 evaluable patients with at
least a single lesion >0.5 cm in diameter (p = 0.019).
Of note, a subset of patients treated on this phase II trial had recurrent ovarian
carcinoma rather than refractory disease. Recurrent ovarian carcinoma, as defined by
the Memorial group, is disease which has responded to initial therapy but which has
recurred with a treatment-free interval of >1 year. Previous experience with ovarian
carcinoma and other tumor types has suggested that second responses may occur in
relapsing patients when the same or similar treatment is employed in individuals who
have not received any treatment for a significant period of time (usually at least one
year) [74-76]. In contrast to the experience in patients with refractory disease (no
treatment-free interval), where responses were seen principally in individuals with the
smallest tumor volumes, patients with recurrent disease had a high response rate
independent of the bulk of tumor present at the initiation of treatment. These data
support the argument that following intraperitoneal delivery ofcisplatin there will be
significant delivery of cisplatin to the tumor by capillary flow. It also emphasizes the
difficulty encountered when attempting todefine the precise role played by intraperito-
neal drug delivery, as responses observed may be due to systemic drug uptake. The
major difference in response rates based on the volume ofdisease in the refractory
population suggests, however, that the route ofdrug administration is important in this
clinical setting.
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BIOLOGICAL AGENTS DELIVERED BY THE INTRAPERITONEAL
ROUTE IN THE MANAGEMENT OF OVARIAN CARCINOMA
A numberofbiological agents have been delivered by theintraperitoneal routein the
managment ofovarian carcinoma [77]. Justification for this approach is similar to that
described for cytotoxic drugs, with the additional theoretical argument that high
peritoneal cavity drug levels may result in the augmentation of local immunoregula-
tory mechanisms. Responses, including surgically defined complete remissions, have
been observed in refractory ovarian carcinoma. Ofnote, as with cytotoxic chemothera-
py, these major responses have been seen almost exclusively in patients with very
small-volume residual disease [77,78]; however, even patients wiht bulky intra-
abdominal disease and intractable ascites have been shown to experience clinically
important palliation of symptoms secondary to a reduction in malignant fluid
reaccumulation. Despite early promising results employing biological agents when
administered by the intraperitoneal route, a precise role for this treatment strategy in
the management ofovarian carcinoma remains to be defined.
CONCLUSION
Intraperitoneal therapy has evolved from a highly investigative treatment strategy
into a form of treatment which can, under certain circumstances, be considered a
reasonable option in the standard management ofovarian carcinoma. It remains to be
determined, however, ifthe responses observed in the refractory disease setting can be
translated into a major survival advantage for patients treated in this manner.
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